CAR T Cell On-Target, Off-Tumor Toxicity in Solid Tumor Treatment: Generation and Management

Authors

  • Tianyi Wang

DOI:

https://doi.org/10.54097/m670m217

Keywords:

CAR T cells, on-target off-tumor toxicity (OTOT), CRS.

Abstract

CAR-T cells involve incorporating T cells with a synthetic receptor to target tumor-specific molecules and this therapy enhances the patients’ own immune system to combat tumors. CAR-T cells are successful to elicit an enduring response to hematological malignancies but remains unsatisfactory during their application in solid tumors. Mostly, OTOT is a main safety concern during trials of CAR-T cells, which has led to destruction of healthy tissues and their normal functions, potentially threatening the patients’ life if damage were done on essential organs. OTOT arises from the CAR-T activation upon normal cells due to presence of tumor-like molecules on their surfaces, accompanied by potential cytokine release syndrome (CRS), which further lyses normal tissues. In this review, the structure and mechanisms of CAR-T cells will be described. More importantly, we will discuss the OTOT generation in CAR-T trials targeting solid tumors and available methods to mitigate this problem for advancing CAR-T application.

Downloads

Download data is not yet available.

References

Mohty, M., Dulery, R., Gauthier, J. et al. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant, 2020.

Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther Oncolytics, 2022, 19 (25): 69-77.

Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol, 2023, 20 (1): 49-62.

Hamieh M, Mansilla-Soto J, Rivière I, Sadelain M. Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. Cancer Discov, 2023, 13 (4): 829-843.

Pan, K., Farrukh, H., Chittepu, V.C.S.R. et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res, 2022.

Benmebarek M-R, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International Journal of Molecular Sciences, 2019, 20 (6): 1283.

Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? Mol Ther, 2020, 28 (11): 2320-2339.

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother Cancer, 2018, 6 (1): 56.

Zhang Y, Li Y, Cao W, Wang F, Xie X, Li Y, Wang X, Guo R, Jiang Z, Guo R. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity". Front Immunol, 2021, 12: 799206.

Robbie G. Majzner, Crystal L. Mackall; Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov, 2018, 8 (10): 1219–1226.

Downloads

Published

29-12-2023